We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03816891
Recruitment Status : Active, not recruiting
First Posted : January 25, 2019
Last Update Posted : September 28, 2022
Sponsor:
Information provided by (Responsible Party):
Kiniksa Pharmaceuticals, Ltd.

Tracking Information
First Submitted Date  ICMJE January 23, 2019
First Posted Date  ICMJE January 25, 2019
Last Update Posted Date September 28, 2022
Actual Study Start Date  ICMJE March 11, 2019
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 17, 2020)
Phase 2a & 2b: Percent change from baseline in Worst Itch Numeric Rating Scale (WI-NRS) [ Time Frame: at Week 8 (Phase 2a); at Week 16 (Phase 2b) ]
Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
Original Primary Outcome Measures  ICMJE
 (submitted: January 23, 2019)
Percent change from baseline in Worst Itch Numeric Rating Scale (WI-NRS) [ Time Frame: Week 8 ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 17, 2020)
  • *Phase 2a: Proportion of subjects achieving at least a 4-point reduction from baseline in weekly average WI-NRS [ Time Frame: at Week 8 ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2a: Percent change from baseline in pruritus visual analog scale (VAS) [ Time Frame: at Week 8 ]
    At every visit, subjects rate intensity of their average pruritus over previous 3 days on 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis)
  • Phase 2a: Change from baseline in weekly average of WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2a: Percent change from baseline in weekly average of WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2a: Change from baseline in pruritis visual analog scale (VAS) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    At every visit, subjects rate intensity of their average pruritus over previous 3 days on 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis)
  • Phase 2a: Percent change from baseline in pruritis visual analog scale (VAS) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    At every visit, subjects rate intensity of their average pruritus over previous 3 days on 0-10 line scale (0=no pruritis, 10=worst imaginable pruritis)
  • Phase 2a: Change from baseline in 5-D Pruritus total score over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Administered every 2 visits, the 5-D Pruritus Scale evaluates pruritus in five domains: duration, degree, direction, disability and distribution. The scores from each domain are added together to obtain a total 5-D score ranging from 5 (no pruritus) and 25 (most severe pruritus)
  • Phase 2a: Percent change from baseline in 5-D Pruritus total score over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Administered every 2 visits, the 5-D Pruritus Scale evaluates pruritus in five domains: duration, degree, direction, disability and distribution. The scores from each domain are added together to obtain a total 5-D score ranging from 5 (no pruritus) and 25 (most severe pruritus)
  • Phase 2a: Proportion of subjects achieving at least a 4-point reduction from baseline in weekly average WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2a: Change from baseline in Sleep Loss VAS over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    At every visit, subjects rate intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness)
  • Phase 2a: Percent change from baseline in Sleep Loss VAS over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    At every visit, subjects rate intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness)
  • Phase 2a: Change from baseline in weekly average of difficulty falling asleep NRS over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Subjects rate difficulty falling asleep daily on Numerical Rating Scale (0=no difficulty, 10=extremely difficult)
  • Phase 2a: Percent change from baseline in weekly average of difficulty falling asleep NRS over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Subjects rate difficulty falling asleep daily on Numerical Rating Scale (0=no difficulty, 10=extremely difficult)
  • Phase 2a: Change from baseline in weekly average of sleep quality NRS over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Subjects rate daily sleep quality on Numerical Rating Scale (0=best possible sleep, 10=worst possible sleep)
  • Phase 2a: Percent change from baseline in weekly average of sleep quality NRS over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    Subjects rate daily sleep quality on Numerical Rating Scale (0=best possible sleep, 10=worst possible sleep)
  • Phase 2a: Change from baseline in quality of life (QoL) measures (DLQI and Itchy QoL) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    QoL is assessed at designated visits and includes the Dermatology QoL Index (DLQI) whereby 0=no effect on quality of life; 30= extremely large effect on QoL; and Itchy QoL, administered as designated visits, which contains 22 items focused on the impact of pruritus on daily activities and on the level of psychological stress. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered)
  • Phase 2a: Percent change from baseline in quality of life (QoL) measures (DLQI and Itchy QoL) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    QoL is assessed at designated visits and includes the Dermatology QoL Index (DLQI) whereby 0=no effect on quality of life; 30= extremely large effect on QoL; and Itchy QoL, administered as designated visits, which contains 22 items focused on the impact of pruritus on daily activities and on the level of psychological stress. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered)
  • Phase 2a: Change from baseline in Prurigo Nodularis Nodule Assessment Tool (PN-NAT) over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    PN-NAT, assessed at designated visits, is a novel exploratory tool for the evaluation of disease severity based on estimate of the number of nodules over the whole body, estimate of hardness of nodules over the whole body, estimate of extent of excoriation over the whole body, distribution of nodules, exact number of nodules in the representative area.
  • Phase 2a: Proportion of subjects with improvement in Prurigo Nodularis Investigator Global Assessment (PN-IGA) by 2 categories over time [ Time Frame: to end of treatment, assessed up to 24 weeks ]
    PN-IGA, assessed at designated visits, is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease)
  • Phase 2b: Proportion of subjects achieving at least a 6-point reduction from baseline in weekly average WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2b: Proportion of subjects achieving at least a 4-point reduction from baseline in weekly average WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) [ Time Frame: at Week 16 ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2b: Proportion of subjects achieving 0 or 1 from baseline in PN-IGA [ Time Frame: at Week 16 ]
    PN-IGA, assessed at designated visits, is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease)
  • Phase 2b: Change from baseline in weekly average of WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2b: Percent change from baseline in weekly average of WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2b: Proportion of subjects achieving at least a 6-point reduction from baseline in weekly average WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2b: Proportion of subjects achieving at least a 4-point reduction from baseline in weekly average WI-NRS (Worst Itch [pruritis] - Numerical Rating Scale; 0=no pruritis, 10=worst imaginable pruritis) over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    Subjects rate pruritus daily on Worst Itch [pruritis] Numerical Rating Scale (0=no pruritus; 10=worst imaginable pruritus)
  • Phase 2b: Proportion of subjects achieving 0 or 1 in PN-IGA over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    PN-IGA is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease)
  • Phase 2b: Proportion of subjects with at least 2-point improvement from baseline in PN-IGA over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    PN-IGA, assessed at designated visits, is a novel exploratory tool for the overall investigator assessment of PN disease severity based on the size of the nodules as defined by their elevation. The IGA utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe disease)
  • Phase 2b: Proportion of subjects achieving 0 or 1 in Investigator's Global Assessment for Prurigo Nodularis-Stage (IGA-CNPG-S) over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    IGA-CNPG-S, administered at designated visits, is a novel tool for the investigator assessment of PN disease severity based on the number of palpable nodules and utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe). A score is assigned based on the appearance of the disease at the time of the evaluation without referring to the baseline state.
  • Phase 2b: Proportion of subjects with at least 2-point improvement from baseline in IGA-CNPG-S over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    IGA-CNPG-S, administered at designated visits, is a novel tool for the investigator assessment of PN disease severity based on the number of palpable nodules and utilizes a 5-point scale that ranges from 0 (clear) to 4 (severe). A score is assigned based on the appearance of the disease at the time of the evaluation without referring to the baseline state.
  • Phase 2b: Change from baseline in weekly average of Sleep Loss VAS over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    At every visit, subjects rate intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness)
  • Phase 2b: Percent change from baseline in weekly average of Sleep Loss VAS over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    At every visit, subjects rate intensity of their average sleeplessness over previous 3 days on 0-10 line scale (0=no sleeplessness, 10=worst imaginable sleeplessness)
  • Phase 2b: Change from baseline in ItchyQoL over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    Itchy QoL, administered as designated visits, contains 22 items focused on the impact of pruritus on daily activities and on the level of psychological stress. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered)
  • Phase 2b: Percent change from baseline in ItchyQoL over time [ Time Frame: to end of treatment, assessed up to 52 weeks ]
    Itchy QoL, administered as designated visits, contains 22 items focused on the impact of pruritus on daily activities and on the level of psychological stress. The frequency items are scored using a 5-point Likert scale ranging from "never" to "all the time". The bother items are scored from 1 (not bothered) to 5 (severely bothered)
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Official Title  ICMJE A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis
Brief Summary Study of the efficacy, safety, tolerability, pharmacokinetics (PK), and immunogenicity of Vixarelimab (KPL-716) in subjects with prurigo nodularis.
Detailed Description

This is a Phase 2a/b randomized, double-blind, placebo-controlled study to investigate the efficacy, safety, tolerability, PK and immunogenicity of Vixarelimab administered subcutaneously (SC) in subjects with prurigo nodularis experiencing pruritus.

Phase 2a portion (completed):

Forty-nine subjects with moderate to severe PN experiencing moderate to severe pruritus were treated in the Phase 2a portion of the study. At Baseline, subjects were randomized 1:1 to receive double-blind Vixarelimab or placebo: Vixarelimab 720 mg loading dose followed by 360 mg every week; Placebo loading dose followed by placebo every week. The treatment Period was 8 weeks or 16 weeks (treatment duration was reduced from 16 weeks to 8 weeks in a protocol amendment [Protocol Version 3]).

Phase 2b portion (enrolling):

The Phase 2b study (Figure 1) will consist of a 4-week Screening Period and a 16-week Double-Blind Period, followed by a 36-week Open-Label-Extension (OLE) Period. Approximately 180 subjects with PN, experiencing severe pruritus, will be randomized (at 1:1:1:1 ratio) into one of 4 arms (3 active arms and one placebo arm). A total of 4 doses of study drug will be administered during the Double-Blind Period to measure the efficacy, safety, and PK of Vixarelimab. After the Double-Blind Period, all subjects will have the option to receive Vixarelimab during the OLE Period to evaluate the long-term safety and PK.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Phase 2a (completed): 2 arms; Phase 2b (enrolling): 5 arms (4 arms during Double Blind Period and 1 arm during Open Label Extension)
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE
  • Prurigo Nodularis
  • Pruritis
Intervention  ICMJE
  • Drug: vixarelimab
    solution for injection
    Other Name: KPL-716
  • Drug: Placebo
    solution for injection
Study Arms  ICMJE
  • Experimental: Phase 2a - Vixarelimab 360 mg SC QW
    Vixarelimab 720 mg loading dose followed by 360 mg weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
    Intervention: Drug: vixarelimab
  • Placebo Comparator: Phase 2a - Placebo SC QW
    Placebo loading dose followed by placebo weekly for 8 weeks (Protocol Version 3) or 16 weeks (Protocol Version 2)
    Intervention: Drug: Placebo
  • Experimental: Phase 2b - Vixarelimab 540 mg SC Q4W (DBL)
    Vixarelimab 540 mg SC, every 4 weeks for 16 weeks during Double Blind Period
    Intervention: Drug: vixarelimab
  • Experimental: Phase 2b - Vixarelimab 360 mg SC, Q4W (DBL)
    Vixarelimab 360 mg SC, every 4 weeks for 16 weeks during Double Blind Period
    Intervention: Drug: vixarelimab
  • Experimental: Phase 2b - Vixarelimab 120 mg SC, Q4W (DBL)
    Vixarelimab 120 mg SC, every 4 weeks for 16 weeks during Double Blind Period
    Intervention: Drug: vixarelimab
  • Placebo Comparator: Phase 2b - Placebo SC, Q4W (DBL)
    Placebo SC, every 4 weeks for 16 weeks during Double Blind Period
    Intervention: Drug: Placebo
  • Experimental: Phase 2b - Vixarelimab 360 mg SC, Q2W (OLE)
    Vixarelimab 360 mg SC, every 2 weeks for 36 weeks during Open Label Extension
    Intervention: Drug: vixarelimab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: September 26, 2022)
190
Original Estimated Enrollment  ICMJE
 (submitted: January 23, 2019)
100
Estimated Study Completion Date  ICMJE August 2023
Estimated Primary Completion Date December 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria (apply to both Phase 2a and Phase 2b unless otherwise specified):

  1. Male or female aged 18 to 75 years (Phase 2a), 18 to 80 years (Phase 2b)
  2. Have clinical diagnosis of prurigo nodularis for at least 6 months
  3. Have at least 10 nodules (Phase 2a), 20 nodules (Phase 2b) at the Screening Visit and Day 1
  4. Moderate to severe pruritus (Phase 2a); severe pruritus (Phase 2b)
  5. Female subjects of childbearing potential must have a negative pregnancy test, be nonlactating, and having agreed to use a highly effective method of contraception, as specified in the protocol, from the Screening Visit until 16 weeks after final study drug administration
  6. Able to comprehend and willing to sign an Informed Consent Form and able to abide by the study restrictions and comply with all study procedures for the duration of the study

Exclusion Criteria (apply to both Phase 2a and Phase 2b unless otherwise specified):

  1. Use of prohibited medications within the indicated timeframe from Day 1
  2. Is currently using medication known to cause pruritus
  3. Presence of any inflammatory, pruritic, and/or fibrotic skin condition other than moderate to severe prurigo nodularis or atopic dermatitis unless approved by the Sponsor
  4. Laboratory abnormalities that fall outside the windows specified in the protocol at the Screening Visit
  5. Has an active infection, including skin infection
  6. Any medical or psychiatric condition which, in the opinion of the Investigator or the Sponsor, may place the subject at increased risk as a result of study participation, interfere with study participation or study assessments, affect compliance with study requirements, or complicate interpretation of study results
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Austria,   Belgium,   Canada,   Czechia,   France,   Germany,   Italy,   Korea, Republic of,   Poland,   Taiwan,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03816891
Other Study ID Numbers  ICMJE KPL-716-C201
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party Kiniksa Pharmaceuticals, Ltd.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Kiniksa Pharmaceuticals, Ltd.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: John Paolini, M.D. Kiniksa Pharmaceuticals, Ltd.
PRS Account Kiniksa Pharmaceuticals, Ltd.
Verification Date September 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP